Atypical Hemolytic Uremic Syndrome Market To Reach New Heights In Growth By 2034, Delveinsight Predicts
Atypical Hemolytic Uremic Syndrome market Forecast. DelveInsight's Atypical Hemolytic Uremic Syndrome Market report offers an in-depth understanding of the ...
rarediseaseadvisor1mon
Ravulizumab May Be Beneficial for Patients With Thymoma-Associated MG
Ravulizumab had an early and sustained clinical effect which contributed to the avoidance of intubation. A patient with thymoma-associated myasthenia gravis (MG) was successfully treated with ...
National Institute for Health and Care Excellence1mon
Published guidance, NICE advice and quality standards
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma TA997 29 August 2024 29 August 2024 ...
rarediseaseadvisor1mon
Ravulizumab May Be a Suitable Alternative to High-Dose Eculizumab in PNH
Ravulizumab offers an extended dosing interval of 8 weeks compared with 2 weeks for eculizumab. Researchers reported positive findings of a phase 4 clinical trial designed to assess the safety and ...
Business Wire1mon
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting
In PNH patients experiencing substantial extravascular hemolysis while receiving ravulizumab, zaltenibart monotherapy resulted in sustained clinically meaningful improvements in both hemoglobin ...